Bausch Health Companies Inc (BHC) Stake Decreased by Korea Investment CORP
Korea Investment CORP trimmed its holdings in Bausch Health Companies Inc (NYSE:BHC) by 45.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 22,092 shares of the company’s stock after selling 18,344 shares during the period. Korea Investment CORP’s holdings in Bausch Health Companies were worth $408,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. ValueAct Holdings L.P. purchased a new position in Bausch Health Companies during the 3rd quarter worth $462,911,000. Vanguard Group Inc. purchased a new position in Bausch Health Companies during the 3rd quarter worth $223,173,000. Vanguard Group Inc purchased a new position in Bausch Health Companies during the 3rd quarter worth $223,173,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Bausch Health Companies by 0.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 8,452,664 shares of the company’s stock worth $156,267,000 after purchasing an additional 75,175 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new position in Bausch Health Companies during the 3rd quarter worth $135,538,000. Hedge funds and other institutional investors own 53.02% of the company’s stock.
Shares of NYSE:BHC opened at $23.98 on Friday. Bausch Health Companies Inc has a 12-month low of $14.95 and a 12-month high of $28.45. The firm has a market capitalization of $8.39 billion, a PE ratio of 5.97, a P/E/G ratio of 0.30 and a beta of 0.58. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 8.55.
BHC has been the topic of several research reports. Morgan Stanley set a $32.00 price objective on Bausch Health Companies and gave the stock a “buy” rating in a report on Monday, December 17th. HC Wainwright upgraded Bausch Health Companies from an “average” rating to a “buy” rating in a report on Friday, December 14th. UBS Group upgraded Bausch Health Companies to a “buy” rating in a report on Wednesday, January 2nd. Mizuho restated a “buy” rating and set a $39.00 price objective on shares of Bausch Health Companies in a report on Sunday, January 6th. Finally, Zacks Investment Research upgraded Bausch Health Companies from a “hold” rating to a “buy” rating and set a $27.00 price target on the stock in a report on Tuesday, January 29th. Three analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $27.61.
In other Bausch Health Companies news, CEO Joseph C. Papa acquired 30,000 shares of the stock in a transaction dated Thursday, February 28th. The stock was purchased at an average price of $23.67 per share, with a total value of $710,100.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 11.54% of the stock is owned by company insiders.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Featured Story: Bid-Ask Spread
Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.